Egil Støre Blix
Hege Oma Ohnstad,
Egil Støre Blix,
Lars Andreas Akslen,
Bjørnar Gilje,
Sunil Xavier Raj,
Helle Skjerven
m.fl.:
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)
Katarina Puco,
Gro Live Fagereng,
Sigmund Brabrand,
Pitt Niehusmann,
Egil Støre Blix,
Eli Sihn Samdal Steinskog
m.fl.:
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncologica 2024 DOI
Jürgen Geisler,
Peeter Karihtala,
Malgorzata Tuxen,
Antonis Valachis,
Cecilia Ahlin,
Cathrine Bergquist Fosskaug
m.fl.:
Current treatment landscape of HR+/HER2− advanced breast cancer in the Nordics: a modified Delphi study
Oleksii Nikolaienko,
Hans Petter Eikesdal,
Elisabet Ognedal Berge,
Bjørnar Gilje,
Steinar Lundgren,
Egil Støre Blix
m.fl.:
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
Synnøve Yndestad,
Christina Engebrethsen,
A. Herencia-Ropero,
Oleksii Nikolaienko,
Olav Karsten Vintermyr,
Reidun Kristine Lillestøl
m.fl.:
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer
Albulena Mecinaj,
Geeta Gulati,
Siri Lagethon Heck,
Espen Holte,
Morten Wang Fagerland,
Alf Inge Larsen
m.fl.:
Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial
Thomas Helland,
Bjørn Naume,
Steinar Hustad,
Ersilia Bifulco,
Jan Terje Kvaløy,
Anna Barbro Sætersdal
m.fl.:
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
Hans Petter Eikesdal,
Synnøve Yndestad,
Asmaa Elzawahry,
Alba Llop-Guevara,
Bjørnar Gilje,
Egil Støre Blix
m.fl.:
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Lars Ottestad,
Line Fronth,
Sajitha Rajendiran,
Liv Hege Aksnes,
Hans Petter Eikesdal,
Egil Støre Blix
m.fl.:
Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
Acta Oncologica 2019 DOI
Sigurd Hald,
Mehrdad Rakaee,
Inigo Zubiavrre Martinez,
Elin Richardsen,
Samer Al-Saad,
Erna Elise Paulsen
m.fl.:
LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival
Clinical Lung Cancer 2018 DOI
Giulio Francolini,
Mette S. Thomsen,
Esben S. Yates,
Carine Kirkove,
Ingelise Jensen,
Egil Støre Blix
m.fl.:
Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1
Radiotherapy and Oncology 2017 DOI
Ahmed R. Eldesoky,
Giulio Francolini,
Mette S. Thomsen,
Esben S. Yates,
Tine B. Nyeng,
Carine Kirkove
m.fl.:
Dosimetric assessment of an Atlas based automated segmentation for loco-regional radiation therapy of early breast cancer in the Skagen Trial 1: A multi-institutional study
Clinical and Translational Radiation Oncology 2017 DOI
Egil Støre Blix,
Anne Husebekk
:
Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies
Leukemia and Lymphoma 2016 DOI
AR Eldesoky,
ES Yates,
TB Nyeng,
MS Thomsen,
HM Nielsen,
P Poortmans
m.fl.:
Internal and external validation of an ESTRO delineation guideline - dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer.
Radiotherapy and Oncology 2016 DOI
Kari Flo,
Egil Støre Blix,
Anne Husebekk,
Anders Thommassen,
Andreas Tendeland Uhre,
Tom Wilsgaard
m.fl.:
A longitudinal study of maternal endothelial function, inflammatory response and uterine artery blood flow during the second half of pregnancy
Acta Obstetricia et Gynecologica Scandinavica 2016 DOI
Egil Støre Blix,
Anders Benjamin Kildal,
Eirin Listau Bertelsen,
Anders Waage,
June Myklebust,
Arne Kolstad
m.fl.:
Content of endothelial progenitor cells in autologous stem cellgrafts predict survival after transplantation for multiplemyeloma
Egil Støre Blix,
Jonathan M. Irish,
Anne Husebekk,
Jan Delabie,
Lise Forfang,
Anne Tierens
m.fl.:
Phospho-spesific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
Ingrid Dyvik,
Gro Live Fagereng,
Tonje Lien,
Vigdis Nygaard,
Laxmi Silwal-Pandit,
J Christopher Noon
m.fl.:
Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: A sub-project of the IMPRESS-Norway trial.
2024
Åslaug Helland,
Eli Sihn Samdal Steinskog,
Egil St⊘re Blix,
Åsmund Flobak,
Sigmund Brabrand,
Katarina Puco
m.fl.:
Hever kvaliteten på behandling av kreft
Camilla Øvrebø ONDRČKOVA,
Åslaug Helland,
Egil Støre Blix,
Daniel Heinrich,
Kristina Yvonne Kathe Lindemann
:
ESMO-kongressen 2023 – dette gleder kreftlegene seg til
20. oktober 2023
Åslaug Helland,
Hege Elisabeth Giercksky Russnes,
Gro Live Fagereng,
Khalid Ibrahim Al-Shibli,
Yvonne Andersson,
Thomas Berg
m.fl.:
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5)
Journal of Translational Medicine 2022 DOI
Åslaug Helland,
Hege Elisabeth Giercksky Russnes,
Gro Live Fagereng,
Khalid Ibrahim Al-Shibli,
Yvonne Andersson,
Thomas Berg
m.fl.:
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
Egil Støre Blix
:
A national precision cancer medicine implementation initiative for Norway
Nature Medicine 2022 DOI
Egil Støre Blix
:
Åslaug Helland og Egil Blix, • IMPRESS–Norway - hvordan går det?
2022
Egil Støre Blix
:
Persontilpasset medisin hos pasienter med brystkreft
2019
Hans Petter Eikesdal,
Synnøve Yndestad,
Egil Støre Blix,
Steinar Lundgren,
Geirfinn Vagstad,
Helge Espelid
m.fl.:
Neoadjuvant olaparib monotherapy in primary triple negative breast cancer
2019
Hans Petter Eikesdal,
Christina Clausen,
Egil Støre Blix,
Steinar Lundgren,
Geirfinn Vagstad,
Helge Espelid
m.fl.:
Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer
2019
Mona Stedenfeldt,
Pål Øian,
Mika Gissler,
Egil Støre Blix,
Jouko Pirhonen
:
Authors' reply: Risk factors for obstetric anal sphincter injury after a successful multicentre interventional programme
BJOG: An International Journal of Obstetrics and Gynaecology 2014 DOI
Kari Flo,
Anne Husebekk,
Åse VÅrtun,
Egil Støre Blix,
Tom Wilsgaard,
Ganesh Acharya
:
A longitudinal study of maternal vascular reactivity, circulating endothelial progenitor celss and inflammatory response during the second half of pregnancy
Pregnancy Hypertension 2013
Mona Stedenfeldt,
Jouko Pirhonen,
Egil Støre Blix,
Tom Wilsgaard,
Barthold Vonen,
Pål Øian
:
Epsiotomy characterisitics and risk for anal sphincter injuries: a case-control study
Acta Obstetricia et Gynecologica Scandinavica 2012
Egil Støre Blix,
Jonathan M. Irish,
Anne Husebekk,
Jan Delabie,
Anne Tierens,
June Myklebust
m.fl.:
Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients
British Journal of Haematology 2012 DOI
Mona Stedenfeldt,
Jouko Pirhonen,
Egil Støre Blix,
Tom Wilsgaard,
Barthold Vonen,
Pål Øian
:
ANAL INCONTINENCE AND SEXUAL PROBLEMS IN WOMEN WITH EPISIOTOMY - A MATCHED CASE-CONTROL STUDY
Neurourology and Urodynamics 2012
Egil Støre Blix,
Anne Husebekk
:
Endothelial progenitor cells (EPC)- expression and function in cancer
Regional forskningskonferanse innen medisin og helse 2006
Egil Støre Blix,
Anne Husebekk
:
Endothelial progenitor cells (EPC)-expression and function in cancer
2006
De 50 siste resultatene fra Cristin vises på siden. Se alle arbeider i Cristin her →